About OriGene
OriGene is a Healthcare company based in Rockville (United States) founded in 1996. Proteins, antibodies, and molecular tools are manufactured for research applications. OriGene has raised $69.55 million across 11 funding rounds from investors including Kleiner Perkins, Uni-President and HHS. OriGene has completed 3 acquisitions, including Blue Heron Bio, Marligen Biosciences and biocheckinc.com. Its website origene.com draws about 122 thousand monthly visits. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Kits and Reagents. Its legal entity is ORIGENE TECHNOLOGIES, INC. Its competitors include GenScript, Teknova and Meridian Bioscience; 1 of its 3 listed competitors has raised funding.
Company details
OriGene Technologies is focused on developing proteins, antibodies, and other molecular tools to support the academic, pharmaceutical, and biotech companies in their research of gene functions and drug discovery. Its product lines include the large cDNA and shRNA clone collections, about 5k purified human proteins, monoclonal antibodies (TrueMAB), 140k validated human tissues, and protein microarray products. It also provides a range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from the Companys tissue collection.
- Total Equity Funding$69.55M (USD)
in 11 rounds
- Latest Funding Round$17.05M (USD), Series D
Jun 2015
- InvestorsKleiner Perkins
& 10 more
- Investments & AcquisitionsBlue Heron Bio
& 2 more
Apps and channels of OriGene
its YouTube channel OriGene Technologies Inc. has 4.44K subscribers and 30 videos.
Videos from OriGene
The most watched videos on OriGene's YouTube channel, OriGene Technologies Inc. (4.44K subscribers). Click a video to play it here.
More on OriGene Technologies Inc..
Funding Insights of OriGene
OriGene has successfully raised a total of $69.55M across 11 strategic funding rounds. The most recent funding activity was a Series D round of $17.05 million completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $69.55M
- Total Rounds 11
- Last Round Series D — $17.05M
- Investors Count 11
Latest 10 of 11 funding rounds of OriGene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2015 | $17.05M | Series D | – | Cathay Capital, Merieux Developement | – |
| Mar 2014 | $200,000 | Series C | – | – | – |
| Mar 2013 | $21.3M | Series C | – | – | |
| Sep 2012 | $15M | Series B | – | – | – |
| Jun 2010 | $256,200 | Grant | – | – | |
| May 2010 | $256,200 | Grant | – | – | |
| Mar 2010 | $16M | Series B | – | Zero2IPO Ventures, IDG Capital | |
| May 2008 | $140,000 | Grant | – | – | – |
| Jan 2006 | $164,000 | Grant | – | – | – |
| Jun 2005 | Grant | – | – |
11 investors in total: 11 institutional.
Investors in OriGene
OriGene has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, Uni-President and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Cathay Capital is engaged in global investment and transformation. | cathaycapital.com | Paris, France | ||
| merieux-developpement.com | ||||
Venture capital firm | idgcapital.com | New York, United States | ||
Venture capital investments are directed toward multiple sectors. | 2006 | qimingvc.com | Shanghai, China | |
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States | |
| bjhhtvc.com | ||||
| zero2ipovc.com | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Dairy products, beverages, snacks, and instant noodles are produced. | 1967 | uni-president.com | Tainan, Taiwan | |
VC and private equity investments are made in China-US companies. | morningside.com.cn | Shanghai, China |
Investor details for OriGene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of OriGene
23 people are tracked at OriGene (8 in leadership, 15 in team).
| Name | Role | Group |
|---|---|---|
Xuan Liu | Sr. VP and General Manager of Research Reagent and eCommerce | Leadership |
Wei-Wu He | CEO | Leadership |
Rich Hamer | Vice President | Leadership |
Dezhong Yin | Director and Department Head of Molecular Biology | Leadership |
Tiffany Cone-Henson | Director of Customer Success and Sales | Leadership |
Wei Fu | Vice President of antibody development | Leadership |
Boyang Chu | Director, Protein Department (Wuxi, China) | Leadership |
David Luong, SPHR | Head of Human Resources | Leadership |
Qiuyan | Application Scientist 2 | Team |
Qi Ren | Antibody Development Manager | Team |
Eden Zewdu | Research Associate | Team |
Yaochao Li | sales | Team |
Bailey Gilmore | Research Associate II | Team |
Zhu-Sheng Lan | Product Manager of Pathology Business | Team |
Tom Vitale | Sr. Scientist | Team |
Enidris Siurano-Rodriguez | Human Resources Coordinator | Team |
robert luo | sr. scientist | Team |
Julian Heller | Research Associate II | Team |
Seongseop (John) Kim | Technical Support Manager | Team |
Yichen Guo, Ph.D. | Scientist in Antibody and Assay | Team |
3 more people are available in the full profile.
Complete people profiles for OriGene
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OriGene
OriGene has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Blue Heron Bio, Marligen Biosciences and biocheckinc.com.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
In-vitro diagnostic kits and research reagents are developed and marketed. | biocheckinc.com | Foster, United States | 1997 | Feb 2014 | •••• | |
Gene synthesis and sequencing services are provided using proprietary technology. | blueheronbio.com | Bothell, United States | 1999 | Aug 2010 | •••• | |
Limited information available | marligen.com | Ijamsville, United States | 2001 | Oct 2009 | •••• |
Complete acquisition details for OriGene
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of OriGene
6 dated milestones of OriGene across 19 years, from founding to its latest funding, stage changes and deals.
- Founded OriGene is founded.
- Funding First funding round.
- Acquisition Acquires Marligen Biosciences.
- Acquisition Acquires Blue Heron Bio.
- Acquisition Acquires biocheckinc.com.
- Funding Latest funding round, Series D, of $17.1M.
Competitors of OriGene
OriGene has 3 listed competitors in our database, 1 of them funded. They include GenScript, Teknova and Meridian Bioscience.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| teknova.com | 1996 | Hollister, United States | 290 | Molecular biology reagents and kits are supplied for research applications. | ||
| meridianbioscience.com | 1976 | Ohio, United States | Molecular diagnostic device and kits |
Detailed competitors of OriGene
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of OriGene
The website of OriGene (origene.com) receives about 122.1K visits a month.
- Monthly visits122.1K
▲ 11% vs previous month
Websites whose visitors overlap most with OriGene. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
addgene.org | addgene.org | 100% | #84,256 | – | |
| sinobiological.com | 98% | 188.9K | #224,370 | View details | |
| genecopoeia.com | 93% | 17.2K | #1,512,108 | View details | |
| biochain.com | 87% | 20.6K | #1,374,754 | View details | |
| genscript.com | 86% | 456.1K | #94,888 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for OriGene
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as OriGene (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Origene
Complete news archive for OriGene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OriGene
OriGene was founded in 1996 and raised its 1st funding round 8 years after it was founded.
OriGene is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
OriGene is a funded company, having raised a total of $69.55M across 11 funding rounds to date.
OriGene Technologies is focused on developing proteins, antibodies, and other molecular tools to support the academic, pharmaceutical, and biotech companies in their research of gene functions and drug discovery. Its product lines include the large cDNA and shRNA clone collections, about 5k purified human proteins, monoclonal antibodies (TrueMAB), 140k validated human tissues, and protein microarray products. It also provides a range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from the Companys tissue collection.
OriGene's top competitors include Meridian Bioscience, GenScript and Teknova.
OriGene has made 3 acquisitions, including Blue Heron Bio, Marligen Biosciences, and biocheckinc.com.
OriGene has 11 investors. Key investors include Kleiner Perkins, Uni-President, HHS, Qiming Venture Partners, and NHGRI.
OriGene operates through Origene Technologies, Inc..
The website of OriGene receives about 122 thousand visits a month.